Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy

<p>Nature Cancer, Published online: 23 October 2025; <a href="https://www.nature.com/articles/s43018-025-01056-4">doi:10.1038/s43018-025-01056-4</a></p>Majzner and colleagues show that engineering T cells with a membrane-tethered version of the signaling adaptor molecule SLP-76 alongside a chimeric antigen receptor (CAR) enhances CAR T cell activity against low-antigen-density tumors.